These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39085148)

  • 21. Efficacy and safety of dupilumab plus topical tacrolimus for atopic dermatitis in 6- to 12-year-old patients.
    Gao SS; Chen M; Wang R; Chen JG
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9830-9837. PubMed ID: 37916349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study.
    Zhou B; Peng C; Li L; Liu R; Zhu L; Chen X; Li J
    Front Med (Lausanne); 2022; 9():838030. PubMed ID: 35402441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
    Napolitano M; Fabbrocini G; Neri I; Stingeni L; Boccaletti V; Piccolo V; Amoruso GF; Malara G; De Pasquale R; Di Brizzi EV; Diluvio L; Bianchi L; Chiricozzi A; Di Guida A; Del Duca E; Moschese V; Di Lernia V; Dragoni F; Gruber M; Hansel K; Licari A; Manti S; Leonardi S; Mastorino L; Ortoncelli M; Provenzano E; Palermo A; Patella V; Peduto T; Pezzolo E; Piras V; Potestio L; Battista T; Satta R; Termine S; Palma P; Zangari P; Patruno C
    Paediatr Drugs; 2022 Nov; 24(6):671-678. PubMed ID: 36028611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
    Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
    Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.
    Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
    Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
    Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
    Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab in Elderly Patients With Severe Atopic Dermatitis.
    Russo F; Milanesi N; Cartocci A; Bruzziches F; Tronconi G; Lazzeri L; D'erme AM; Bagnoni G; Gola M; Cinotti E; Rubegni P; Flori ML
    Dermatitis; 2021 Oct; 32(1S):S24-S27. PubMed ID: 33332865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Dupilumab in Chinese Elderly Patients with Atopic Dermatitis: A Real-World Study.
    Hu YQ; Zhang JZ; Zhao Y
    Dermatology; 2024; 240(4):589-596. PubMed ID: 38797168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study.
    Beck LA; Bissonnette R; Deleuran M; Nakahara T; Galus R; Coleman A; Gherardi G; Xiao J; Dingman R; Xu C; Avetisova E; Dubost-Brama A; Shabbir A
    JAMA Dermatol; 2024 Aug; 160(8):805-812. PubMed ID: 38985486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
    Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
    Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
    Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.
    Zheng Y; Ding RL; Bu J
    Front Immunol; 2024; 15():1367099. PubMed ID: 38812522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
    Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
    O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
    Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis.
    Clabbers J; Boesjes C; Spekhorst L; van Gisbergen MW; Maas E; Marshall J; Janssen R; Janssen M; Zuithoff N; Steijlen P; de Graaf M; van Geel M; de Bruin-Weller M; Gostyński A
    J Allergy Clin Immunol; 2024 Apr; 153(4):1155-1161.e4. PubMed ID: 38272373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab.
    Martinez-Cabriales S; Marcoux D; Liy-Wong C; Prajapati VH; Sibbald C; Cunningham N; Lansang P; Tonkin R; Joseph M; Wong L; Spring S; Gavigan G; Ramien M
    Pediatr Dermatol; 2024; 41(1):5-11. PubMed ID: 37906120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improve the dupilumab therapy evaluation with dermoscopy and high-frequency ultrasound in moderate-to-severe atopic dermatitis.
    Liu Z; Niu Z; Zhang D; Liu J; Zhu Q
    Skin Res Technol; 2023 Jan; 29(1):e13260. PubMed ID: 36704877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of dupilumab treatment on general health-related work productivity of adult atopic patients.
    Napolitano M; Fabbrocini G; Nocerino M; Potestio L; Patruno C
    Ital J Dermatol Venerol; 2022 Jun; 157(3):228-230. PubMed ID: 35274879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study.
    Torres T; Paiva-Lopes MJ; Gonçalo M; Claro C; Oliveira M; Gomes J; Vieira AP; Amoedo P; Alpalhão M; Nogueira M; Santiago F; Henrique M; Amaro C; Esteves T; Alves J; Cerejeira D; Mendes-Bastos P; Pestana M; Ramos L; Rocha J; Carvalho R; Teixeira L; Selores M; Mota A; Filipe P;
    J Dermatolog Treat; 2022 Aug; 33(5):2554-2559. PubMed ID: 35083945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.
    Chia SY; Wee LWY; Koh MJA
    Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.